[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eye-dryness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eye-dryness":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100597171","low-level-light-therapy-versus-intense-pulsed-light-to-prevent-iatrogenic-dry-eye-disease-after-cataract-surgery-100597171",false,"NCT07055022","Low-level Light Therapy Versus Intense Pulsed Light to Prevent Iatrogenic Dry Eye Disease After Cataract Surgery","Low-level Light Therapy Versus Intense Pulsed Light to Prevent Iatrogenic Dry Eye Disease After Cataract Surgery: a Randomised Controlled Trial","EDACS","Inclusion Criteria:\n\n* aged ≥50 years\n* scheduled for bilateral cataract surgery by phacoemulsification\n* without current DED treatment, including eye drops, for at least two months before the inclusion\n* with preoperative OSDI ≤22 points, indicating absence of DED or mild DED\n* who signed the informed consent and are willing to comply with the protocol requirements based on the investigator's judgment\n* affiliated with a social security scheme\n* with an ability to answer questionnaires and to communicate freely in French.\n\nExclusion Criteria:\n\n* set to undergo implantation of a multifocal intraocular lens\n* using contact lenses\n* with any of the following in the included eye: (i) age-related macular degeneration (AMD), (ii) previous ocular surgery, (iii) abnormal clinical exam of the ocular surface or (iv) undergoing any ocular treatment\n* with systemic contraindications, including autoimmune diseases (e.g., Sjögren syndrome)\n* with general contraindications for LLLT or IPL treatment: dark pigmented skin (Fitzpatrick grade ≥5), skin photosensitivity (regardless if innate, pathological or medically-induced), or neurological light sensitivity (e.g. epilepsy, light-induced migraines)\n* with contraindications for LLLT or IPL treatment limited to the treatment area: history of skin cancer, skin pigmented lesions, as well as fixed\u002Fpermanent skin piercings, face tattoos, semi-permanent make-up (including microblading) or skin defects\n* with any concomitant disease or disorder which, in the opinion of the investigator, may put the patient at risk or may influence the result of the study\n* with protected status under articles L1121-6, LL121-8 and L1122-2 of the French Public Health Code\n* who cannot comply with the protocol requirements based on the investigator's judgment.","ALL","50 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Dry eye disease (DED) is a frequent ocular surface disease (OSD) of multifactorial origin, characterised by disruption of tear film homeostasis and associated with ocular discomfort and\u002For visual disturbance. Cataract surgery, which is one of the most often performed interventions worldwide, can induce or worsen the symptoms of DED. Despite lack of guidelines on DED prophylaxis before cataract surgery in the general population, there is a growing interest in this topic due to the high prevalence of postoperative DED. A recent randomised controlled trial (RCT) with one month follow-up showed that prophylactic low-level light therapy (LLLT) before and after cataract surgery in patients without pre-existing DED significantly improved postoperative tear film stability, as well as reduced ocular discomfort, compared to no prophylaxis. Apart from LLLT, another light-based treatment for DED is intense pulsed light (IPL); the treatments have shown favourable outcomes in the management of DED, both as stand-alone choices or in combination.",[27,28],"Cataract Surgery","Eye Dryness",[30,31,32,33,34,35,36,37,38,39,40],"IPL","LLLT","Intense Pulse Light","Low Level Light Therapy","cataract surgery","phacoemulsification","prophylaxis","prevention","eye dryness","dry eye disease","DED","NOT_YET_RECRUITING","2025-07-07",{"date":44,"type":45},"2025-07-08","ACTUAL",{"date":47,"type":21},"2025-09-30",{"date":49,"type":21},"2026-06-30",{"name":51,"class":52},"Clinique Trenel","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100591857","phase-3-clinical-trial-for-the-evaluation-of-safety-and-efficacy-of-drop-04-100591857","NCT06985875","Clinical Trial for the Evaluation of Safety and Efficacy of Drop 0.4%","Clinical Trial for the Evaluation of the Safety and Efficacy of a Moisturizing Solution With Hyaluronic Acid Drop 0.4%","DROP04","INCLUSION CRITERIA:\n\n* Male or female, aged 18 years or older, capable of freely providing informed consent for participation in the study.\n* Signed informed consent form prior to any study-related tests.\n* Signed data protection form prior to any study-related tests.\n\nAdditionally, for Group 1 (Non contact lens users)\n\n* Ocular surface disease index (OSDI) ≥ 13\n* No use of contact lenses in the past month and not planning to use them during the study period.\n\nAdditionally, for Group 2 (contact lens users)\n\n* Contact lens dry eye questionnaire (CLDEQ-8) ≥ 12\n* Contact lens (CL) use with a habitual minimum use of 4 days per week and 4 hours per day in the past month.\n\nEXCLUSION CRITERIA:\n\n* Any active ocular surface disease except for dry eye disease.\n* Severe dry eye, defined as meeting at least one of the following criteria in at least one eye:\n\n  * Corneal fluorescein staining ≥ 4 on the Oxford scale (0-5).\n  * Conjunctival lissamine green staining ≥ 4 on the Oxford scale (0-5).\n  * Schirmer test value ≤ 2 mm.\n  * Tear stability (BUT) of 0 seconds.\n* History of ocular surgery in the last 3 months or refractive corneal surgery in the last 6 months.\n* History of herpetic keratitis or uveitis.\n* History of severe ocular infections or inflammation in the 6 months prior to the study.\n* History of allergies affecting the ocular surface during the study period.\n* Patients who have started or are expected to modify the use of the following topical medications during the study (except for artificial tears\u002Fmoisturizing and lubricating solutions):\n\n  * Calcineurin inhibitors (cyclosporine, tacrolimus, etc.) in the 12 weeks prior to the study.\n  * Corticosteroids or non steroid anti-inflammatory drugs (NSAID) in the 4 weeks prior to the study.\n  * Blood-derived treatments (autologous serum, enriched plasma, etc.), insulin, or amniotic preparations in the week prior to the study.\n* Use of systemic medication with potential effects on the tear film that has been started or modified in the last month or is expected to change during the study.\n* Known sensitivity or intolerance to any of the products used in the study.\n* Subjects with clinically relevant or uncontrolled systemic diseases in the last 3 months that may interfere with study assessments or outcomes.\n* Pregnancy or breastfeeding. Lack of effective contraceptive methods in women of childbearing potential.\n* Participation in a clinical trial within the last 30 days.","18 Years","99 Years",{"count":65,"type":21},79,[67],"PHASE3","The aim of the trial is to compare the safety and efficacy of the moisturizing solution DROP 0.4% with the moisturizing solution AVIZOR EYE DROPS 0.2% PRESERVED in relieving the symptoms of dry eye over one month of use.",[28],[71],"contact lens, dry eye","2025-07-04",{"date":74,"type":45},"2025-07-09",{"date":76,"type":21},"2025-07",{"date":78,"type":21},"2025-12-31",{"name":80,"class":81},"Avizor SA","INDUSTRY"]